Sirtuins In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Sirtuins In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Sirtuins are a family of NAD+-dependent deacetylases that regulate cellular metabolism, stress response, and longevity. SIRT1 and SIRT2 are the most studied sirtuins in the nervous system, with well-documented roles in neurodegeneration.
| Sirtuin |
Location |
Primary Function |
Neurodegeneration Role |
| SIRT1 |
Nucleus/cytoplasm |
Deacetylase, metabolism |
Neuroprotection |
| SIRT2 |
Cytoplasm |
Tubulin deacetylation |
Mitochondrial function |
| SIRT3 |
Mitochondria |
Stress response |
Antioxidant |
| SIRT4 |
Mitochondria |
Metabolism |
Insufficiently characterized |
| SIRT5 |
Mitochondria |
Urea cycle |
Insufficiently characterized |
| SIRT6 |
Nucleus |
DNA repair |
Insufficiently characterized |
| SIRT7 |
Nucleolus |
Ribosome biogenesis |
Insufficiently characterized |
SIRT1 is a NAD+-dependent deacetylase that:
- Deacetylates histones — Promotes chromatin silencing
- Regulates PGC-1α — Mitochondrial biogenesis
- Modulates p53 — Reduces p53-mediated apoptosis
- Activates FOXO — Stress resistance
- Deacetylates NF-κB — Reduces inflammation
- Amyloid metabolism — SIRT1 affects APP processing
- Tau pathology — Deacetylates tau, promotes clearance
- Synaptic plasticity — Required for memory formation
- Neuroinflammation — Reduces microglial activation
- SIRT1 expression — Reduced in AD brain
- APOE interaction — ε4 allele affects SIRT1 signaling
- PICALM — Linked to SIRT1 pathway
- NAD+ depletion — Impairs SIRT1 activity in AD
| Approach |
Mechanism |
Status |
| Resveratrol |
SIRT1 activator |
Clinical trials |
| SRT2104 |
Synthetic SIRT1 agonist |
Phase I |
| NAD+ precursors |
Boost SIRT1 substrate |
Investigational |
SIRT1 protects dopaminergic neurons through:
- Mitochondrial function — PGC-1α deacetylation
- α-Synuclein — Reduces aggregation
- Autophagy — Promotes protein clearance
- Stress resistance — FOXO activation
- SIRT1 activators protect against MPTP
- LRRK2 mutations affect SIRT1 pathway
- NAD+ levels decline in PD brain
SIRT1 modulates Huntington's disease pathology:
- HTT acetylation — Promotes clearance of mutant huntingtin
- Transcriptional regulation — Corrects dysregulated genes
- Mitochondrial function — PGC-1α activation
- Autophagy — Enhances mutant protein clearance
- SIRT1 activators reduce mutant HTT aggregation
- Resveratrol improves motor function in models
- NAD+ supplementation shows promise
SIRT2 is primarily a cytoplasmic sirtuin:
- Tubulin deacetylation — Affects cytoskeleton
- Cell cycle regulation — Mitotic checkpoint
- Mitochondrial function — Metabolic regulation
- Stress response — Oxidative stress handling
- Tau deacetylation — SIRT2 deacetylates tau
- Microtubule function — Affects tau pathology
- Neuroinflammation — Modulates glial activation
- SIRT2 increased in AD brain
- SIRT2 inhibition reduces tau pathology
- Complex role — both protective and detrimental
- α-Synuclein aggregation — SIRT2 affects clearance
- Mitochondrial dysfunction — Alters metabolic regulation
- Stress response — Oxidative stress handling
- SIRT2 inhibition protects dopaminergic neurons
- SIRT2 knockout reduces MPTP toxicity
The interplay between SIRT1 and SIRT2 is critical:
flowchart TD
A[NAD+] --> B[SIRT1 Activity]
A --> C[SIRT2 Activity]
B --> D[PGC-1α Activation]
B --> E[FOXO Activation]
B --> F[Anti-apoptotic]
C --> G[Tubulin Deacetylation]
C --> H[Cell Cycle]
C --> I[Metabolic Regulation]
D --> J[Mitochondrial Biogenesis]
E --> K[Stress Resistance]
F --> L[Neuronal Survival]
NAD+ is the essential cofactor for sirtuin activity:
- Age-related decline — NAD+ decreases with age
- Neurodegeneration — Further depleted in disease
- Therapeutic target — Boost NAD+ to activate sirtuins
| Precursor |
Mechanism |
Clinical Status |
| Nicotinamide riboside (NR) |
NAD+ precursor |
Clinical trials |
| Nicotinamide mononucleotide (NMN) |
NAD+ precursor |
Phase I/II |
| Nicotinamide (NAM) |
NAD+ precursor |
Approved |
| Drug |
Target |
Indication |
Status |
| Resveratrol |
SIRT1 |
AD, PD |
Phase II |
| SRT2104 |
SIRT1 |
AD |
Phase I |
| SRT3024 |
SIRT1 |
PD |
Preclinical |
| EX-527 |
SIRT2 |
PD |
Research |
- NAD+ precursors + SIRT1 activators
- SIRT1/SIRT2 modulators + autophagy enhancers
- Metabolic interventions + sirtuin activation
Sirtuins In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sirtuins In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Michan et al., SIRT1 is essential for normal cognitive function (2010)
- Gao et al., SIRT1 and Alzheimer's disease (2022)
- Liu et al., SIRT2 in Parkinson's disease (2019)
- Jiang et al., NAD+ metabolism in neurodegeneration (2021)
- Wu et al., Resveratrol and neurodegeneration (2023)